6 July 2020
Oxford University’s LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19
3 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford. The Ebola vaccine has already been deployed in the North Kivu region of the Democratic Republic of the Congo (DRC), following recommendation from the WHO’s Strategic Advisory Group of Experts (SAGE), and in Rwanda – following conditional approval in 2019 under an ‘exceptional emergency’ – as part of outbreak containment efforts in the region.
2 July 2020
Ghana cut malaria deaths by 65% from 2005 to 2015. In a paper published in the Malaria Journal, Rima Shretta estimates that the COVID-19 outbreak threatens this progress, as lockdowns limit access to health facilities and preventive malaria interventions have been interrupted. Ghana’s transition to a lower middle income status results in lower donor support for malaria control, and the government must step up to avert a feared rise in cases.
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
29 June 2020
The RECOVERY trial was established in March as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV. There was no significant difference in the primary endpoint of 28-day mortality, and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay. The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed that treatment arm.
COVID-19 and the generation, dissemination, and use of evidence. For public-health decision-making or for profit?
22 June 2020
Blog by Piero Olliaro, Professor of Poverty-Related Infectious Diseases and ISARIC Director of Science, following the publication - and retraction - of scientific articles about the risks of treating COVID-19 with (hydroxy)chloroquine. This calls for the reflection on how decisions are made, how the underlying ‘evidence’ is generated and disseminated, and how exposed and vulnerable to manipulation the system we rely upon is.
17 June 2020
The Conversation article, by Lakshmi Manoharan, Medical Epidemiologist. Widespread protests have broken out across the US in response to the killings of black Americans at the hands of police. Demonstrations have also erupted in the UK and other countries in solidarity with the Black Lives Matter movement and in protest at these countries’ own domestic cases of institutional racism. These protests are happening in the middle of a pandemic, which raises issues regarding the spread of the virus, and also highlights deep inequalities due to structural racism and its effects on people’s health. Although health authorities rightly discourage congregations of people, these protests may be the only way for the systemically disenfranchised to have their voices heard.
Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19
16 June 2020
The RECOVERY trial tests a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Patients were randomised to receive dexamethasone 6 mg once per day for ten days and were compared with patients receiving usual care alone. Dexamethasone reduced deaths by one-third in ventilated patients and by one-fifth in other patients receiving oxygen only; there was no benefit among those patients who did not require respiratory support. Based on these results, 1 death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone.
5 June 2020
A new statement has been released from Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY Trial. RECOVERY was established in March as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. The chief investigators have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.
20 May 2020
The COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world’s biggest trial of potential COVID-19 treatments, RECOVERY.
12 May 2020
The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.
5 May 2020
The Global Health Network and the Family Larsson Rosenquist Foundation (FLRF) launch LactaHub: an open access knowledge platform featuring scientific and evidence-based information on breastfeeding and breastmilk for health professionals
30 April 2020
The results of a placebo-controlled randomised trial of remdesivir in COVID-19 patients have been published in the Lancet. Supported by the ISARIC Support Centre, scientists in China launched a trial of remdesivir in patients hospitalised with COVID-19. The results found no clinical benefit from use of the drug; however, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir.
27 April 2020
The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) is producing a weekly report using clinical data from its COVID-19 database. To date, this includes data from 19,809 individuals from 244 sites across 25 countries.
25 April 2020
Blog by Rima Shretta, Honorary Visiting Research Fellow. As the COVID-19 pandemic continues its path to LMICs, its impact is likely to be even more devastating, potentially reversing recent gains made in the management of other communicable diseases. Of particular concern is the impact of the COVID-19 pandemic on malaria. COVID-19 has been slow to arrive and spread across Africa; nevertheless, there are many reasons to be concerned about malaria within the current context of the COVID-19 pandemic.
24 April 2020
A site team in Malawi used the WWARN Malaria Clinical Trials Toolkit for their antimalarial-antiretroviral drug-drug interaction trial with pregnant women. Clifford Banda and his staff used the CDISC-compliant WWARN REDCap data base template as the basis for their data collection and capture, and used or adapted the many WWARN standard operating procedures and their forms for various administrative, clinical, investigational product, quality, data management and safety aspects of their planned work.
17 April 2020
The UK government is funding 21 new novel coronavirus research studies, including a project led by Professor Trudie Lang. Research must be undertaken everywhere across the globe during this pandemic. Access and ability to undertake research should be equitable, and this research project, working through The Global Health Network, aims to support healthcare teams in low-resource settings. This is a University of Oxford led programme aiming to enable more and better research in diseases, communities and settings where evidence is lacking.
10 April 2020
Global health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.
The RECOVERY Trial, which is testing potential treatments for COVID19, has recruited 1000 patients in 15 days
6 April 2020
The world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment. A number of promising treatments are being tested and, if the science supports it, will be given to NHS patients as quickly as possible. Definitive results on whether the treatments are safe and effective are expected within months and, if positive, they could potentially benefit hundreds of thousands of people worldwide. Almost 1,000 patients from 132 different hospitals have been recruited in just 15 days and thousands more are expected to join the Randomised Evaluation of COV-id19 thERapY (RECOVERY) trial in the coming weeks, making it the largest randomised controlled trial of potential COVID-19 treatments in the world.
30 March 2020
The problem of substandard and falsified (SF) medical products affects all countries but few regulatory authorities or pharmaceutical companies have policies of publicly releasing data. As a first step in tracking this global issue, IDDO’s Medicine Quality Research Group, with the MORU Tropical Health Network and supported by a grant from the Wellcome Trust, has today launched a new, free-to-use, online tool, the Medicine Quality Monitoring Globe, (MQM Globe) which maps SF news reports worldwide in real time.
23 March 2020
Oxford Nuffield Department of Population Health started a new trial of potential treatments for adults patients hospitalised with confirmed COVID-19 with the collaboration of Professor Peter Horby
13 March 2020
NDM is prioritising collaborative projects for front line actions to support global efforts in tackling nCoV. ISARIC has launched a number of international resources available free of charge, through which investigators retain full control of data and samples. Gavin Screaton and Guy Thwaites are looking at neutralising antibody responses. Other NDM researchers work on vaccine development, structure, protective immune response, UK hospital settings and pathogens evolution.
10 March 2020
Trudie Lang is cited as one of the five main players who have helped restore British faith in the value of experts. Trudie has consistently warned that the medical profession needs to learn lessons from the current coronavirus outbreak: “This is not going to be the last outbreak of a previously unknown disease and we have to strengthen the research capabilities of nations where new diseases emerge but which currently have the poorest ability to respond.”
4 March 2020
From April 2020, an existing successful Health Protection Research Unit will be bolstered by the addition of collaborators from the University of Oxford. Funded by NHIR, the next phase of the HPRU in Emerging and Zoonotic Infections will build on the work already done by the University of Liverpool, the Liverpool School of Tropical Medicine, and Public Health England.
28 February 2020
A statistical analysis of WWARN data from 4,214 participants across multiple study sites in Africa has been published in BMC Medicine. Results indicate that the local prevalence of resistance-associated markers should be considered when choosing a first-line drug to ensure optimal duration of protection.
13 February 2020
What do a mathematician, an epidemiologist, a vaccine developer, a protein crystallographer and a whole bevy of immunologists and infectious disease specialists have in common? Answer: they’re just some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak. Science blog by Charvy Narain
11 February 2020
The International Day of Women and Girls in Science recognises and celebrates the critical role played by women but also aims to promote their full and equal access to participation in science. However, despite more women than ever working across the sciences, it is still a male-dominated field with only 30% of female researchers, according to UNESCO. IDDO asked colleagues across their networks for their views. How we could encourage more women into science? And what changes are needed in order to keep them in science?
International research consortium activates clinical study for novel coronavirus in England and Scotland
31 January 2020
In response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.
28 January 2020
Governments, funders, and research bodies must take action to ensure that research is undertaken ethically during global health emergencies, says a new report from the Nuffield Council on Bioethics.
28 January 2020
This pop-up space for 2019 Novel Coronavirus (2019-nCoV) supports evidence generation by pooling protocols, tools, guidance, templates, and research standards generated by researchers and networks working on the response to this outbreak. Findings from previous outbreaks, largely obtained during MERS and SARS outbreaks, are also available. We aim to make research faster and easier, and to enable standardised, quality data to be collected and prepared for sharing.
22 January 2020
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is adapting its existing tools, designed for emerging respiratory pathogens, for the current outbreak of global significance. This is an international resource for facilitating the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with novel coronavirus.
17 January 2020
A specialist technique used to study drugs has been completed for the first time during an outbreak of Ebola virus disease.
Global study highlights the extent and impact of drug-resistant enteric fever and the urgent need for new approaches
23 December 2019
A new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.
3 December 2019
Oswaldo Cruz Foundation (Fiocruz) is a leading institution of science and a public health in Latin America. The new online knowledge hub launched on 3rd December 2019 and feature virtual courses, information and news about the Foundation.
19 November 2019
Oxford University has been ranked as the world's best institution for medical and health teaching and research for the ninth consecutive year in the latest Times Higher Education World University Rankings. The ranking is based on criteria measuring teaching, research, industry income, international outlook and citations, which are combined to provide a comparison of universities worldwide.
14 November 2019
Life-saving Instruction for Emergences (LIFE), a virtual reality (VR) medical training platform developed by doctors, nurses and researchers at the KEMRI-Wellcome Trust Research Programme (KWTRP) in Kenya and Oxford University with support from HTC, has officially launched today. This new virtual reality medical training app uses HTC VIVE Focus Plus for training doctors and nurses to save lives.
8 November 2019
Noting that substandard and falsified medical products (including medicines, vaccines, biologics, and diagnostics) represent a significant and growing threat to human health, The Lancet Global Health published 'The Global access to quality-assured medical products: the Oxford Statement and call to action'. The Oxford Statement has been signed by 159 attendees at the 2018 Oxford Conference on Medicine Quality and Public Health from governments, multilateral agencies, academia and civil society.
MSc in International Health and Tropical Medicine well represented at the Medical Sciences Divisional 2019 Teaching Awards
28 October 2019
Congratulations to Proochista Ariana (Major Educator Award), Kevin Marsh (Lifetime Achievement Award), Caroline Jones (Excellent Supervisor Award), Vicki Marsh (Excellent Teacher Award), Prabin Dahal (Early Career Excellent Teacher Award), and Judy Irving (Learning Support Award) who were recognised at the 2019 Teaching Excellence Awards Ceremony, at Merton College on Wednesday 23 October.
16 October 2019
When we are ill, we trust that the medicines that we take will make us feel and be better. But what if our pills do not contain the ingredients listed on the packaging? The art exhibition ‘What’s in your medicines?’ explores how substandard and falsified (‘fake’) medicines can affect our health, by showcasing the striking and original artwork of 12 South East Asian artists.
9 October 2019
Oxford Medical Sciences Divisional Panel has conferred the title of Professor on three members of our Centre. Ben Cooper - Professor of Epidemiology, Sassy Molyneux - Professor of Global Health and Piero Olliaro - Professor of Poverty Related Infectious Diseases were awarded these titles in recognition of their distinction in their respective fields and contributions to the research, teaching and administration of the Department and we congratulate them on their success!
8 October 2019
The Africa Oxford Initiative (AfOx) is a cross-university network that brings the University of Oxford’s long-standing, multi-disciplinary engagement with Africa under one platform. The overarching goal of AfOx is to ensure Africa remains a strategic priority for the University, and that students and academics who attend from the Continent feel supported and at home while they are here.
4 October 2019
The Oxford based OHSCAR team is delighted to be a partner the NEST360 project working with KEMRI-Wellcome and the Kenya Paediatric Research Consortium in Kenya to support this effort to improve care care of the sick newborn and save lives
1 October 2019
Oxford University is running a campaign to celebrate Black History Month. Throughout October the university will amplify the annual celebration with a series of content streams and events recognising and appreciating the contributions that BME communities make to society and the university itself. From academics to students, staff and alumni, the campaign will shine a light on black people’s achievements, and echo the growing call for inclusion in all areas of life from education to cultural appreciation.
18 September 2019
This report presents research on the current state of governance and coordination of health emergency preparedness and response. It highlights key challenges to address for the future. The report was commissioned by the Global Preparedness Monitoring Board to inform their inaugural report launched on 18th September 2019.
17 September 2019
Two researchers from the Centre for Tropical Medicine and Global Health were awarded medals by the Royal Society of Tropical Medicine and Hygiene at the 2019 European Congress on Tropical Medicine and International Health. Professor David Warrell was awarded the Sir Patrick Manson Medal, and Dr Samson Kinyanjui the Chalmers Medal.
6 August 2019
IDDO has launched a new global Chagas scientific collaboration with the Drugs for Neglected Diseases initiative (DNDi). The new platform will collate and standardise data to accelerate better treatments for the 6–7 million people worldwide with Chagas disease.
Latest research finds primaquine improves haemoglobin by day 42 following treatment of P. vivax malaria
1 August 2019
An IDDO/WWARN study has found that primaquine is not associated with increased levels of anaemia following treatment of patients without G6PD deficiency for P. vivax malaria and should be used as part of a radical cure. In the largest study of its kind to date, researchers carried out a systematic review and individual patient data meta-analysis which involved 3,421 patients in 29 studies published in BMC Medicine.
Better Research for Better Health: University of Oxford and Fiocruz partner to improve health research and capacity development globally
31 July 2019
A new strategic partnership between Fiocruz and The Global Health Network will amplify the impact of Fiocruz’s health research and capacity development initiatives by promoting research capacity building across Portuguese-speaking countries, and enabling research findings from the Zika outbreak to benefit public health worldwide.
28 June 2019
IDDO’s visceral leishmaniasis (VL) collaboration is working on two new projects looking at the treatment of VL. The first is a systematic review of the literature on design and analysis of antileishmanial clinical efficacy studies, and the second is a systematic review of published studies to estimate the baseline risk of serious adverse events and mortality in patients treated with antileishmanial therapies.
14 June 2019
WWARN Researcher Debashish Das has been involved in clinical research in various settings in Asia and Africa with the Mahidol-Oxford Tropical Medicine Research Unit (MORU) and Médecins Sans Frontières (MSF). His research efforts focus on investigating antimalarial drug resistance and finding treatment solutions for young children